These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Long-term clinical results with the Starr-Edwards Model 6120 mitral valve prosthesis].
    Author: Imanishi K.
    Journal: Nihon Kyobu Geka Gakkai Zasshi; 1994 Jun; 42(6):914-23. PubMed ID: 8057025.
    Abstract:
    This investigation included 101 patients who had Starr-Edwards silicone ball prosthesis (Model 6120) implanted at the Tokyo Women's Medical College Daini Hospital from 1981 to 1991. A cumulative total of follow-up was 657.0 pt-years. For these patients 102 prostheses were used. The mean follow-up period was 6.5 +/- 3.3 (0.2-11.9) years, and follow-up data were obtained for 100% of the patients. This investigation examined all valve related morbidity and mortality. Late deaths occurred in 14 patients. Thromboembolism occurred in 19 patients, for a predicted freedom from this complication of 82.8% at 5 years, and 78.2% at 10 years. The linearized rate of late death due to thromboembolism was 2.9%/pt-year. There were four cases of anticoagulation-related hemorrhage (ACH), one case of endocarditis and two cases of valve failure. The linearized incidence of ACH was 0.6%/pt-year, that of PVE was 0.2%/pt-year and that of valve failure was 0.3%/pt-year. The estimated actuarial survival was 95% at one year, 86.6% at 5 years and 80% at 10 years. The performance characteristics of the Starr-Edwards Ball Valve (Model 6120) in our institute showed superior structural durability of this prosthesis. Conclusions; 1) The high level of structural durability of the Starr-Edwards Ball Valve (Model 6120) was reconfirmed. 2) This study demonstrated a high level of clinical performance of the SEBV Model 6120. 3) Risk factors affecting the late death and thromboembolism were analyzed.
    [Abstract] [Full Text] [Related] [New Search]